Basic Information
| LncRNA/CircRNA Name | CDKN2B-AS1 |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Gemcitabine | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder urothelial cancer |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, etc. |
| Sample | BUC tissues, cell lines (SV-HUC-1, J82, T24) |
| Expression Pattern | up-regulated |
| Function Description | LncRNA CDKN2B-AS is high-expressed in BUC and related to low Gemcitabine sensitivity of BUC. CDKN2B-AS inhibited Gemcitabine sensitivity through Wnt signaling pathway in BUC. |
| Pubmed ID | 29937935 |
| Year | 2018 |
| Title | Long non-coding RNA CDKN2B antisense RNA 1 gene inhibits Gemcitabine sensitivity in bladder urothelial carcinoma. |
External Links
| Links for CDKN2B-AS1 | GenBank HGNC NONCODE |
| Links for bladder urothelial cancer | OMIM COSMIC |